Home » Stocks » TARA

ArTara Therapeutics, Inc. (TARA)

Stock Price: $18.99 USD -0.12 (-0.63%)
Updated Jan 22, 2021 1:01 PM EST - Market open
Market Cap 214.26M
Revenue (ttm) n/a
Net Income (ttm) -26.78M
Shares Out 6.32M
EPS (ttm) -6.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $18.99
Previous Close $19.11
Change ($) -0.12
Change (%) -0.63%
Day's Open 19.11
Day's Range 18.76 - 19.48
Day's Volume 60,240
52-Week Range 16.76 - 60.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 2 days ago

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has...

Other stocks mentioned: AKUS, PMVP
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare disease...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...

GlobeNewsWire - 2 months ago

- On T rack to Complete GMP Batch Runs in Mid-2021 to C onfirm C omparability B etween TARA-002 and OK-432 - - Expect to I nitiate Phase 1 T rial for TARA-002 in P atients with N on- M uscle I...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare disease...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare disease...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dise...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare dise...

GlobeNewsWire - 4 months ago

- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -

About TARA

Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therap... [Read more...]

Industry
Biotechnology
CEO
Jesse Shefferman
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
TARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is 45.67, which is an increase of 140.49% from the latest price.

Price Target
$45.67
(140.49% upside)
Analyst Consensus: Strong Buy